Evidence map›Paper›PMID 42108733›Full record

ArticleJournal of gynecologic oncology2026

Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer.

Asami Matsunaga, Miho Ogawa, Akiko Kunita, Yuji Ikeda, Kosuke Kashiwabara, Yuki Okuma, Osamu Kobayashi, Nobuki Hayashi, Takahiro Nakajima, Qian Xi and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Asami Matsunaga *Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0005-4593-1794
Miho Ogawa *Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0005-8685-2099
Akiko KunitaNext-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0008-9989-8258
Yuji IkedaDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1633-5385
Kosuke KashiwabaraData Science Office, Clinical Research Promotion Center, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6115-1193
Yuki OkumaDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0007-4205-3353
Osamu KobayashiDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0007-5366-2883
Nobuki HayashiDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6916-8555
Takahiro NakajimaDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0003-8184-9275
Qian XiDivision of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0008-6436-5515
Mirei KaDivision of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0001-8950-8948
Saki KamataDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0001-9260-2505
Keisuke SaitouDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0004-2177-4344
Yoko NakanishiDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5022-4676
Shinobu MasudaDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0361-8071
Kousuke WatanabeNext-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4670-3679
Aya Shinozaki-UshikuDivision of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0196-5643
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1763-8380
Hidenori KageDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3658-4442
Kei KawanaDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1919-8830
Katsutoshi OdaDivision of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. odak@g.ecc.u-tokyo.ac.jp.ORCID https://orcid.org/0000-0002-2468-9573

Funding

Japan Agency for Medical Research and Development JP21km0908001Japan Society for the Promotion of Science 24K02584Japan Society for the Promotion of Science 25K20079Konica Minolta Co., Ltd.
6 · The paper itself

Abstract

objectiveCirculating tumor human papillomavirus (HPV) DNA (ctHPV DNA) has shown clinical utility in advanced cervical cancer; however, its role in surgically resected disease remains unclear. We evaluated the detectability and clinicopathological associations of ctHPV DNA in preoperative plasma from patients with surgically resected cervical cancer using digital polymerase chain reaction (dPCR).

methodsWe analyzed 49 surgically resected cervical cancer patients. HPV genotyping of formalin-fixed paraffin-embedded tumor tissues was performed using both PGMY09/11 consensus PCR and novel genotype-specific dPCR assays targeting 6 high-risk HPV types (16, 18, 31, 39, 45, and 52). Plasma cell-free DNA was analyzed using dPCR for HPV genotypes. Associations between ctHPV DNA copy number and clinicopathological features were evaluated.

resultsHPV genotypes were identified in 42 of 49 tumor tissues (85.7%), with dPCR showing superior sensitivity (95.8%) compared to the PGMY method (77.6%). ctHPV DNA was detected in 12 of 42 evaluable plasma samples (28.6%), and plasma genotypes were concordant with those of the corresponding tumor tissues. ctHPV DNA copy numbers were significantly higher in cases with lymphovascular invasion (p=0.034) and lymph node metastasis (p=0.010), but were not correlated with tumor size, stage, or histologic type. ctHPV DNA was more consistently detectable than

conclusionThis study highlights ctHPV DNA as a promising noninvasive biomarker in surgically resected cervical cancer. Its association with lymphovascular invasion and lymph node metastasis supports its potential role in preoperative risk stratification and personalized surgical planning.

Indexed as

Circulating Tumor DNADNA, ViralHuman Papillomavirus VirusesPapillomaviridaePapillomavirus InfectionsPolymerase Chain ReactionUterine Cervical NeoplasmsAdultAgedFemaleGenotypeHumansLymphatic MetastasisMiddle AgedCirculating Tumor DNADNA, ViralBiomarkerCirculating Tumor DNAGenotyping TechniquesHPV Human PapillomavirusPolymerase Chain ReactionUterine Cervical Neoplasms

Identifiers

PMID42108733
PMCPMC13655338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.